[go: up one dir, main page]

US4313936A - Biologically active substance, its preparation and compositions containing it - Google Patents

Biologically active substance, its preparation and compositions containing it Download PDF

Info

Publication number
US4313936A
US4313936A US06/140,818 US14081880A US4313936A US 4313936 A US4313936 A US 4313936A US 14081880 A US14081880 A US 14081880A US 4313936 A US4313936 A US 4313936A
Authority
US
United States
Prior art keywords
shoulder
process according
strong
cells
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/140,818
Other languages
English (en)
Inventor
Jean Florent
Jean Lunel
Denise Mancy
Bernard Vuillemin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Industries SA
Original Assignee
Rhone Poulenc Industries SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Industries SA filed Critical Rhone Poulenc Industries SA
Application granted granted Critical
Publication of US4313936A publication Critical patent/US4313936A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/265—Micrococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/859—Micrococcus

Definitions

  • This invention relates to a new biologically active substance, hereinafter designated by the number 41,200 RP, which is obtained from cells isolated from a culture of a new microorganism designated by the name Micrococcus sedogenes M 78, to a process for its preparation and to pharmaceutical compositions containing it.
  • the substance 41,200 RP according to the present invention is obtained after treating, with lysozyme, the cells isolated from Micrococcus sedogenes, M 78 strain, precipitating the impurities by means of calcium chloride, removing the proteins by treatment with phenol, and then fractionating the product on a molecular sieve.
  • the cells used to prepare the aqueous suspension are preferably dried beforehand and optionally heated at a temperature of the order of 120° C., i.e. of from 110° to 130° C., at a pH of about 3, i.e. of from 2 to 4, for 30 to 60 minutes.
  • the lysozyme is used at a rate of 2 to 20 mg per gram of dried cells employed.
  • the treatment with lysozyme is preferably carried out at a constant pH of about 7 preferably for 2 hours, and the treatment is generally effected whilst stirring vigorously.
  • the liquid phase of the resulting suspension is generally separated off by centrifugation and the dissolved products of low molecular weight are removed either by dialysis across a membrane of suitable porosity or by ultrafiltration.
  • the crude substance thus obtained can be isolated in the form of a salt by lyophilising its solution.
  • the crude substance Dissolved in water at a concentration of between 10 and 40 grams per liter, preferably 20 grams per liter, the crude substance is generally purified by adding a concentrated solution of calcium chloride until a final concentration of calcium chloride of between 5 and 50 grams per liter, preferably 10 grams per liter, is obtained.
  • the precipitate formed is removed by centrifugation and the resulting solution is dialysed (or ultrafiltered) and then treated with an ion exchange resin carrying a sulphonic acid group in the alkaline form.
  • the substance obtained which is designated by the number 32,919 RP, can be separated from its aqueous solution by lyophilisation.
  • the substance 32,919 RP is purified again, preferably by the following procedure:
  • An aqueous solution of the substance 32,919 RP in which the concentration of the substance 32,919 RP is between 10 and 50 grams per liter, preferably 25 grams per liter, is washed with an equal volume of a phenol/water mixture (preferably containing 10% (w/w) of water) for 15 to 60 minutes, preferably 30 minutes, at a temperature of the order of 65° C. in order to remove the greater part of the proteins.
  • aqueous phase is separated off and washed with a chlorinated hydrocarbon solvent, preferably chloroform, until the dissolved phenol has been removed, and is then dialysed against distilled water.
  • the aqueous phase containing the active substance is lyophilised.
  • the product thus obtained is dissolved in water buffered to pH 7 using an alkali metal acetate such as sodium acetate.
  • the solution thus obtained is subjected to fractionation on a molecular sieve of high porosity, such as "Ultragel Ac A 22" from the Industrie Bitician Francaise, or "Sepharose 4 B” or “Sepharose CL 4B” from the Societe Pharmacia, the high molecular weight fraction, i.e. from 5 ⁇ 10 5 to 5 ⁇ 10 6 , being collected.
  • the substance 41,200 RP obtained is then isolated from its solution by lyophilisation, after prolonged dialysis against demineralised water.
  • the substance 41,200 RP may, if desired, be converted by known methods into an alkali metal or alkaline earth metal salt thereof.
  • microorganism Micrococcus sedogenes M 78 strain, of which the culture, under suitable conditions, provides the cells used to prepare 41,200 RP, must be regarded as a new species belonging to the genus Micrococcus.
  • Genus was determined in accordance with the identification key in "Bergey's Manual of Determinative Bacteriology", 7th edition, The Williams and Wilkins Company, Baltimore (1957).
  • the morphological characteristics of the M 78 strain were studied on static cultures kept for 24 hours at 26° C. These cultures consist of immobile, non acid-resistant, Gram-positive coccal cells of diameter 1 ⁇ to 1.3 ⁇ , which are isolated or in groups of two or four cells, or in short chains of 4 to 16 cells, or also in non-uniform agmina of 20 to 50 cells. The presence of spores was not observed.
  • the cultures on nutrient agar slopes have the appearance of a smooth or very slightly rough, odourless, non-chromogenous, abundant greasy coating having a soft consistency.
  • the cultures on nutrient agar in Petri dishes are in the form of circular colonies with uniform edges and a smooth surface; these colonies are flattened or slightly convex and more or less opaque.
  • the cultures in nutrient glucose broth are moderately turbid, do not contain pigment, are odourless and contain a flake-like sediment.
  • the M 78 strain When cultivated on potato, the M 78 strain forms a very pale yellowish-white, smooth greasy coating which does not blacken the potato and does not contain soluble pigment.
  • Respiratory type obligate aerobe
  • Optimum temperature for development 4° C.--no development; 22° C.--good developement; 26° C.--very good development; 30° C.--good development; 37° C.--mediocre development; 45° C.--no development
  • the M 78 strain utilises the following substances, with a moderate or good degree of efficiency, as sources of carbon: starch, ethanol, sodium acetate, sodium propionate, succinic acid, malic acid, sodium citrate and sodium pyruvate.
  • sources of carbon starch, ethanol, sodium acetate, sodium propionate, succinic acid, malic acid, sodium citrate and sodium pyruvate.
  • the following are not utilised or only permit poor development: ribose, arabinose, glucose, lactose, maltose, sucrose, trehalose, glycerol, mannitol, inositol, glutaric acid, sodium tartrate and galacturonic acid.
  • the sources of nitrogen which can be utilised by the M 78 strain for its development were also determined in accordance with Pridham's method, using sodium citrate as the source of carbon and replacing the NH 4 H 2 PO 4 in the base medium by various nitrogen-containing compounds. Under these conditions, the following compounds are utilised with a good or moderate degree of efficiency: NaNO 3 , NaNO 2 , NH 4 H 2 PO 4 , D,L-asparagine, succinimide, glycine, D,L-alanine, D,L-aspartic acid, D,L(+)-glutamic acid, L(-)-tyrosine and D,L-proline. the following are not utilised: adenine, uracil, creatinin, D(+)-glucosamine, sarcosine, L(+)-arginine, D,L-methionine and betaine.
  • the bacterium M 78 is spherical, Gram-positive and an obligate aerobe, reduces nitrates to nitrites, is incapable of fermenting carbohydrates in anaerobiosis and does not form spores; these characteristics make it possible to classify it in the family of the Micrococcaceae (Pribram, 1929).
  • This family is divided into six genera which are split into two groups in accordance with the respiratory type; this distinction makes it possible to classify the bacterium M 78 in the first group, which comprises the genera Micrococcus, Staphylococcus, Gaffkya and Sarcina.
  • This group is split into two sub-groups which are characterised by the manner in which the cells are grouped together.
  • the bacterial cells studied do not occur systematically in tetrads or in groups of eight cells; as a result of this property, the M 78 strain is classified either in the genus Micrococcus or in the genus Staphylococcus.
  • Micrococcus varians those which the M 78 strain could most closely resemble are as follows: Micrococcus varians, Micrococcus caseolyticus and Micrococcus colpogenes.
  • the M 78 strain differs, in particular, from Micrococcus varians in that it does not form acids from glucose, lactose, sucrose, glycerol or mannitol and in that it does not acidify milk.
  • Micrococcus caseolyticus it differs from Micrococcus caseolyticus in that it does not liquefy gelatin, does not peptonise milk and does not produce acids from glucose, lactose, mannitol or glycerol.
  • the M 78 strain is also different from Micrococcus colpogenes by the essential fact that it cannot hydrolyse chitin and that it is also urease-negative.
  • the strain studied exhibits differences, from the described species of the genus Micrococcus, which make it possible to consider it as a new species.
  • the process for the preparation of the cells used to prepare 41,200 RP consists in cultivating Micrococcus sedogenes, M 78 strain, on a suitable medium and under suitable conditions, and then in separating off the cells which have multiplied during cultivation.
  • Micrococcus sedogenes M 78 strain
  • the inoculation and fermentation techniques and the various types of equipment used for this purpose are those commonly used in the fermentation industry.
  • the fermentation medium must contain sources of assimilable carbon, nitrogen, phosphorus and sulphur, inorganic substances and, if appropriate, growth factors. These constituents may be provided in the form of well-defined products or by complex mixtures such as those encountered in biological products of various origins.
  • Sources of assimilable carbon which can be used are carbohydrates, such as dextrins and starch, or other carbon-containing substances, such as alcohols (ethanol) or certain organic acids, e g. lactic acid and citric acid.
  • carbohydrates such as dextrins and starch
  • other carbon-containing substances such as alcohols (ethanol) or certain organic acids, e g. lactic acid and citric acid.
  • ethanol alcohols
  • organic acids e g. lactic acid and citric acid.
  • Certain animal or vegetable oils such as lard oil or soya bean oil, can advantageously replace these various sources of carbon or can be added thereto.
  • Suitable sources of assimilable nitrogen are extremely varied. They may be very simple chemical substances, such as inorganic or organic ammonium salts and certain aminoacids. They can also be provided by complex substances which mainly contain nitrogen in protein form, e.g. casein, lactalbumin, gluten and their hydrolysates, soya bean flour, peanut flour and fish meal, meat extract and yeast extract, soluble residues from the distillation of gran alcohol (distillers' solubles), and corn-steep liquor.
  • the sulphur and the phosphorus are generally provided in a sufficient amount by the complex substances mentioned above. They can also be provided in the form of sulphates and phosphates.
  • Some of the inorganic constituents added can have a buffering or neutralising effect, such as alkali metal or alkaline earth metal phosphates or calcium carbonate or magnesium carbonate. Others contribute to the ionic equilibrium necessary for the development of Micrococcus sedogenes, M 78 strain, such as alkali metal and alkaline earth metal chlorides and sulphates or salts of zinc, cobalt, iron, copper and manganese.
  • the pH of the fermentation medium at the start of cultivation must be between 6.0 and 7.8 and preferably between 6.5 and 7.5.
  • the optimum temperature for the fermentation is between 25° and 30° C. but satisfactory production is achieved at temperatures between 20° and 35° C.
  • the aeration of the fermentation can vary between fairly wide limits. However, it has been found that aerations of 0.3 to 3 liters of air per liter of medium per minute are particularly suitable. The maximum yield is obtained after 8 to 20 hours of cultivation, preferably after 15 hours, the time depending on the medium used.
  • the pH of the fermentation medium at the end of cultivation is generally between 7.3 and 8.8 and it is preferably between 8.0 and 8.4.
  • the microorganism Micrococcus sedogenes, M 78 strain is generally separated from the fermentation medium by filtration or centrifugation, advantageously after the medium has been acidified to a pH of about 3 by adding a mineral acid, such as hydrochloric acid.
  • a mineral acid such as hydrochloric acid.
  • the new substance 41,200 RP according to the present invention exhibits remarkable and useful biological properties.
  • the substance according to the invention significantly increases the resistance of the mice to infection by doses, which are normally fatal, of virulent strains of bacteria, such as Listeria monocytogenes, Staphylococcus aureus and Escherichia coli, and of viruses, such as encephalomyocarditis virus, murine hepatitis virus, influenza viruses (human viruses adapted to mice, type A 0 and A 2 ), herpes virus and Semliki-Forest arbo-virus.
  • doses which are normally fatal, of virulent strains of bacteria, such as Listeria monocytogenes, Staphylococcus aureus and Escherichia coli, and of viruses, such as encephalomyocarditis virus, murine hepatitis virus, influenza viruses (human viruses adapted to mice, type A 0 and A 2 ), herpes virus and Semliki-Forest arbo-virus.
  • 41,200 RP When administered to mice parenterally, 41,200 RP strongly stimulates the phagocytic ability of the reticulo-endothelial system and increases the number of antibody-producing lymphocytes in the spleen. It exerts a stimulating effect on reactions involving delayed-type hypersensitivity and reactions involving the production of antibodies against particulate antigens.
  • tumoral cells such as sarcoma 180 cells
  • 41,200 RP favours rejection of the tumors by causing a necrotic reaction therein.
  • the product according to the invention increases the number and/or the cytolytic activity of the T lymphocytes in the spleen, against allogenic tumoral cells.
  • the active doses are generally between 0.03 and 3 mg/kg animal body weight, and preferably between 0.3 and 1 mg/kg animal body weight. Generally, a single treatment suffices to achieve the desired effect for a period of at least 48 hours.
  • mice In mice, the 50% lethal dose (LD 50 ) of 41,200 RP, administered intravenously, is of the order of 23 mg/kg animal body weight.
  • proteins are expressed according to the aminoacid analysis, glucose is determined by the anthrone method, phosphorus is determined by the molybdate method after ashing, the proportion of nucleic acids is determined by the absorbency at 258 nm, and amino-sugars are determined by the Elson-Morgan method and are expressed in terms of glucosamine, or by determination with ninhydrin, after hydrolysis and separation using a Biotronik LC 6000 E autoanalyser.
  • Peptone (1,200 g), meat extract (600 g), soya bean oil (1,200 cc) and tap water (sufficient to make up to 110 liters) are introduced into a 170 liter fermenter.
  • the pH is adjusted to 6.90 by adding 10 N sodium hydroxide solution and the medium is then sterilised by bubbling steam at 122° C. through it for 40 minutes. After cooling, the volume of the broth is 120 liters because steam has condensed during the sterilisation; the pH of the medium is 6.70. Inoculation is carried out with a culture, produced in a stirred Erlenmeyer flask, of Micrococcus sedogenes, M 78 strain (200 cc).
  • the culture is developed at 27° C. for 14 hours, whilst stirring and aerating with sterile air; it is then suitable for inoculating the production culture.
  • the production culture is carried out in an 800 liter fermenter containing the following: L-lactic acid (4 kg), soya bean oil (2 liters), ammonium sulphate (2.4 kg), sodium chloride (2 kg), monopotassium phosphate (0.4 kg) magnesium sulphate. 7H 2 O (0.8 kg), copper sulphate. 5H 2 O (0.02 kg), zinc sulphate. 7H 2 O (0.012 kg), cobalt chloride. 6H 2 O (0.008 kg) and tap water (sufficient to make up to 370 liters).
  • the pH of the medium is adjusted to 7.10 by adding 10 N sodium hydroxide solution (2,950 cc) and the broth is then sterilised by bubbling steam at 122° C. through it for 40 minutes. After cooling, the volume of the broth is 400 liters because steam has condensed during the sterilisaton; the pH of the broth, which is 4.20, is adjusted to 6.60 by adding a 5 N aqueous solution of sodium hydroxide (2,100 cc).
  • Inoculation is then carried out with 40 liters of the inoculum culture described above, produced in the 170 liter fermenter.
  • the culture is developed at 27° C. for 16 hours, whilst stirring with a stirrer rotating at 205 rpm and aeration with sterile air (15 m 3 /hour).
  • the pH of the culture medium is 8.20 and the volume of the broth is 440 liters.
  • the must thus obtained is cooled to +4° C. and its pH is adjusted to 3 by adding 5 N hydrochloric acid (4 liters).
  • the cells are isolated by centrifugation at 4,000 rpm (2,900 g).
  • the cells are taken up in ethanol (80 liters) at -10° C., by stirring for 15 minutes, and are then isolated by centrifugation and dried at 35° C. under reduced pressure (5 mm Hg) for 15 hours. Dry cells (1,500 g) are thus obtained.
  • Cells (1 kg) prepared as described in (A) are suspended in sterile distilled water (40 liters), in a stainless steel reactor which is equipped with a jacket, the temperature of which is thermostatically controlled by the circulation of water, and with a high-powdered central stirrer.
  • the pH is adjusted to 7.0 by adding 10 N sodium hydroxide solution.
  • Lysozyme (2 g) is then added and the mixture is stirred for 2 hours at 37° C., the pH being periodically readjusted to 7.0 by adding 5 N sodium hydroxide solution.
  • the mixture is then centrifuged on a Sharples M16 machine (2 successive passes at 17,000 rpm with a flow rate of 30 liters per hour).
  • the supernatant (37 liters) is ultrafiltered (UFP 20 apparatus equipped with an Iris 3042 acrylic membrane), the retained material being recycled and demineralised water (3 ⁇ 40 liters), cooled to +4° C., being added.
  • This product (31 g) is dissolved in demineralised water (1,550 cc), at a temperature of about 20° C., by stirring for 30 minutes; an aqueous solution containing 668 g/liter of calcium chloride dihydrate (31 cc) is then added in the course of 5 minutes, whilst stirring constantly; stirring is continued for 30 minutes.
  • the precipitate formed is removed by centrifugation on a Sharples laboratory machine at 40,000 rpm with a flow rate of 5 liters per hour.
  • the supernatant is dialysed on a cellulosic membrane for 3 days, at +4° C., against demineralised water (3 ⁇ 40 liters).
  • the retained material is then treated for 1 hour, in a round-bottomed flask, with Dowex 50 X2 polystyrene-sulphonic resin in the sodium form (310 cc), whilst stirring; the resin is filtered off and washed on the filter with water (310 cc).
  • the wash waters are combined with the filtrate and the whole is lyophilised.
  • proteins sum of the aminoacids
  • nucleic acids 28.9% (according to the UV spectrum).
  • Example (B) The substance 32,919 RP obtained under the conditions of Example (B) (25 g) is dissolved in demineralised water (1 liter) contained in a 2 liter reactor which is equipped with a stirrer and a temperature-regulating device; a phenol/water mixture (109 cc of water to 1 kg of phenol) (1 liter) is added. The mixture is heated to 65° C., whilst stirring vigorously. Stirring is continued for 30 minutes at the same temperature. After rapidly cooling the reactor to a temperature of about 25° C. by means of an ice bath, the phases are separated by centrifugation at 3,300 g, for 30 minutes, on a cooled laboratory machine (Jouan, type K 63 F, with a capacity of 4 liters). 450 cc of aqueous phase are thus obtained.
  • the phenol phase and the intermediate phase are re-extracted with demineralised water (1 liter) for 30 minutes at 65° C; after cooling and centifugation, as indicated above, a further 1,470 cc of aqueous phase are obtained.
  • the aqueous phases are combined.
  • the phenol is removed by successive washings with chloroform (2 ⁇ 2 liters).
  • the aqueous phases are then clarified by centrifugation for 30 minutes at 3,300 g. 1,800 cc of aqueous phase are thus obtained.
  • This clarified aqueous phase is then dialysed for 3 days, at +4° C., against demineralised water (3 ⁇ 40 liters).
  • the retained material is lyophilised and a white amorphous powder (14.5 g) is thus obtained.
  • the resulting solution is poured onto a Sepharose CL 4B column (diameter: 13.5 cm, height: 65 cm) which is installed in a cold chamber (+4° C.) and treated with sterile 0.1 M sodium acetate buffer at pH 7.0. Elution is then carried out with the same buffer at a rate of 1.33 liters/hour and the absorbency at 230 nm, through 0.1 cm of the eluate, is recorded continuously.
  • a fraction of 3.13 liters is initially collected and this is discarded.
  • the following fraction (1.22 liters) which corresponds to an absorbency peak at 230 nm, is introduced into a tube of NOJAX regenerated cellulose and is dialysed for three days at +4° C., against demineralised water (3 ⁇ 40 liters), and the retained material (1,300 cc) is then lyophilised.
  • the solid obtained is taken up in demineralised water (93 cc) and the solution is dialysed, with the same membrane as above, for 48 hours, at +4° C., against demineralised water (2 ⁇ 20 liters).
  • the retained material is lyophilised.
  • UV spectrum this spectrum is shown in FIG. 1;
  • infrared spectrum (determined using KBr discs): this spectrum is shown in FIG. 2, in which the wavelength expressed in microns (upper scale), and the wavenumbers in cm -1 (lower scale) have been plotted on the abscissae and the percentage transmission has been plotted on the ordinate.
  • composition water (Fischer): 3.8%;
  • aminoacids 12.3% (of which 7% is alanine);
  • nucleic acids less than 1.3% (according to the UV spectrum);
  • Example 1(A) The procedure of Example 1(A) is followed. After cultivation for 16 hours, the must is cooled to 4° C. and its pH is adjusted to 3 by adding hydrochloric acid. The cells are isolated by centrifugation at 4,000 rpm. The acid cell cake is then heated in an autoclave for 45 minutes at 122° C. After cooling, the cells are washed with ethanol and then dried.
  • composition water (Fischer): 6%;
  • aminoacids 17.7% (of which 7.2% is alanine);
  • nucleic acids less than 3%
  • compositions comprising 41,200 RP or an alkali metal or alkaline earth metal salt thereof, in association with one or more compatible and pharmaceutically acceptable carriers or diluents and, optionally, at least one other therapeutically active product, such as an antibiotic.
  • these compositions are administered parenterally or intranasally.
  • the invention includes especially such compositions made up for parenteral or intranasal administration.
  • Preparations according to the invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions or emulsions.
  • non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • These compositions may also contain adjuvants, in particular wetting, emulsifying and dispersing agents. They may be sterilized by, for example, incorporation in the compositions of sterilizing agents, or by irradiation using ⁇ rays. They may also be manufactured in the form of sterile solid compositions, which can be dissolved or dispersed in sterile water or some other sterile injectable medium immediately before use.
  • compositions for intranasal administration may be in the form of sterile suspensions, emulsions or aqueous solutions, which may optionally be associated with a compatible propellant.
  • compositions according to the invention are particularly useful in human or veterinary therapy for the immunological treatment (immunotherapy) of cancer, if appropriate in combination with a suitable anti-cancer chemotherapy or during remissions induced by the latter.
  • compositions can also be used for increasing resistance to viral, bacterial, fungal or parasitic infections, for stimulating the natural defences of the organism acting specifically against these infections, for reinforcing, by intranasal administration, the natural barriers against respiratory infections, or for exerting an adjuvant effect on specific immunisation during the concomitant administration of a bacterial, viral or parasitic vaccine.
  • compositions of the invention also make it possible to restore the appropriate immunological responses in the case of subjects showing conditions of immunodeficiency which are congenital or result from senescence or from immunosuppressive treatments.
  • the doses depend on the desired effect and the duration of the treatment; for an adult, they are generally between 0.1 and 10 mg per day, administered parenterally.
  • a solution containing the substance 41,200 RP in the form of a salt (5 g; sterilised beforehand by irradiation with ⁇ rays) in an injectable sterile solution (100 cc) is prepared.
  • This solution is distributed under aseptic conditions, in 5 cc ampoules at a rate of 2 cc per ampoule. The ampoules are sealed. They each contain 100 mg of active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US06/140,818 1979-04-18 1980-04-16 Biologically active substance, its preparation and compositions containing it Expired - Lifetime US4313936A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7909743A FR2454302A1 (fr) 1979-04-18 1979-04-18 Nouvelle substance biologiquement active, sa preparation et les medicaments qui la contiennent
FR7909743 1979-04-18

Publications (1)

Publication Number Publication Date
US4313936A true US4313936A (en) 1982-02-02

Family

ID=9224428

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/140,818 Expired - Lifetime US4313936A (en) 1979-04-18 1980-04-16 Biologically active substance, its preparation and compositions containing it

Country Status (26)

Country Link
US (1) US4313936A (no)
JP (1) JPS5611795A (no)
AT (1) AT370129B (no)
AU (1) AU538492B2 (no)
BE (1) BE882841A (no)
CA (1) CA1122526A (no)
CH (1) CH646873A5 (no)
DE (1) DE3015030A1 (no)
DK (1) DK163980A (no)
ES (1) ES8200920A1 (no)
FI (1) FI67571C (no)
FR (1) FR2454302A1 (no)
GB (1) GB2046759B (no)
GR (1) GR66676B (no)
HU (1) HU181104B (no)
IE (1) IE49446B1 (no)
IL (1) IL59842A (no)
IT (1) IT1209323B (no)
LU (1) LU82370A1 (no)
NL (1) NL8002108A (no)
NO (1) NO155103C (no)
NZ (1) NZ193457A (no)
PT (1) PT71107A (no)
SE (1) SE446344B (no)
SU (1) SU1042602A3 (no)
ZA (1) ZA802271B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2522945B2 (ja) * 1987-06-18 1996-08-07 呉羽化学工業株式会社 抗レトロウィルス剤
CH680192A5 (no) * 1989-12-13 1992-07-15 Nestle Sa
WO1997045530A1 (fr) * 1996-05-27 1997-12-04 UZILOVA, Irina Semenovna, Heiress of UZILOV Utilisation de souches de streptococcus faecium et composition a base de ces souches

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821366A (en) * 1967-02-22 1974-06-28 Rhone Poulenc Sa Antibiotic 19,402 r.p.
US4174390A (en) * 1977-02-07 1979-11-13 Eli Lilly And Company Antibiotic A-7413 and process for preparation thereof
US4180564A (en) * 1978-05-25 1979-12-25 Eli Lilly And Company A-38533 Antibiotics and process for production thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821366A (en) * 1967-02-22 1974-06-28 Rhone Poulenc Sa Antibiotic 19,402 r.p.
US4174390A (en) * 1977-02-07 1979-11-13 Eli Lilly And Company Antibiotic A-7413 and process for preparation thereof
US4180564A (en) * 1978-05-25 1979-12-25 Eli Lilly And Company A-38533 Antibiotics and process for production thereof

Also Published As

Publication number Publication date
AU538492B2 (en) 1984-08-16
AT370129B (de) 1983-03-10
AU5749480A (en) 1980-10-23
NO155103C (no) 1987-02-11
IT8021495A0 (it) 1980-04-18
CA1122526A (fr) 1982-04-27
IE49446B1 (en) 1985-10-02
DE3015030C2 (no) 1988-09-08
FR2454302A1 (fr) 1980-11-14
SE8002898L (sv) 1980-10-19
IT1209323B (it) 1989-07-16
DK163980A (da) 1980-10-19
ZA802271B (en) 1981-04-29
ATA205480A (de) 1982-07-15
HU181104B (en) 1983-06-28
GR66676B (no) 1981-04-08
FI67571C (fi) 1985-04-10
JPS5611795A (en) 1981-02-05
PT71107A (fr) 1980-05-01
GB2046759A (en) 1980-11-19
NL8002108A (nl) 1980-10-21
NO801114L (no) 1980-10-20
CH646873A5 (fr) 1984-12-28
FI801251A (fi) 1980-10-19
GB2046759B (en) 1983-02-23
SE446344B (sv) 1986-09-01
SU1042602A3 (ru) 1983-09-15
IL59842A (en) 1984-02-29
NZ193457A (en) 1983-02-15
DE3015030A1 (de) 1981-05-07
JPS6251275B2 (no) 1987-10-29
NO155103B (no) 1986-11-03
BE882841A (fr) 1980-10-17
FI67571B (fi) 1984-12-31
IL59842A0 (en) 1980-06-30
ES490702A0 (es) 1981-11-16
ES8200920A1 (es) 1981-11-16
FR2454302B1 (no) 1982-05-21
IE800772L (en) 1980-10-18
LU82370A1 (fr) 1980-12-16

Similar Documents

Publication Publication Date Title
Roberts et al. New procedures for purification of L-asparaginase with high yield from Escherichia coli
EP0468411B1 (en) A mutant of bacterium Clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
JPH02257886A (ja) Ｗｓ６０４９―ｂ物質、その製造法およびそれを有効成分として含有する抗癌剤
EP0298641B1 (en) Acid urease and production thereof
US4313936A (en) Biologically active substance, its preparation and compositions containing it
EP0459367B1 (en) Method for preparing an antitumor dextran
FR2520379A1 (fr) Procede de preparation d'un disaccharide-tripeptide et d'un disaccharide-tetrapeptide possedant des proprietes immunostimulantes
KR870001987B1 (ko) 엔듀라시딘의 제조방법
CH639133A5 (de) Verfahren zur herstellung einer antitumor wirksamen substanz mit immunostimulierender wirkung.
KR830002535B1 (ko) 신규 생물학적 활성 물질의 제조방법
JPH0460474B2 (no)
EP0159497B1 (en) Collagenase and production method thereof
US3345269A (en) Process for the production of proteolytic enzymes
SE461532B (sv) Cancermotverkande och immunaktiverande aemne (spf-100)
US3762998A (en) Cultivation of lactobacillus bulgaricus to produce a ribonucleoproteid
US3061516A (en) Telomycin and its production
JPS603476B2 (ja) 抗生物質組成物
EP0024206A2 (en) Antitumor substance, composition comprising it and process for preparing said substance
JP2898022B2 (ja) コラーゲン分解酵素の製造方法
GB2090846A (en) Anti-tumor polysaccharide
US3891753A (en) Antibiotic prenomycin and process of producing the same
EP0091745A1 (en) Preparation of an antibiotic selectively effective against staphylococcus infections
US3565988A (en) Antibiotic
KR910008639B1 (ko) 세라티오 펩티다제의 생산방법
KR820001221B1 (ko) 하이드록시아미노 하이드로카르본포스폰산 유도체의 제조방법

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE